Technical Analysis for CRIS - Curis, Inc.

Grade Last Price % Change Price Change
grade D 1.08 9.09% 0.09
CRIS closed up 9.09 percent on Wednesday, January 16, 2019, on 1.12 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical CRIS trend table...

Date Alert Name Type % Chg
Jan 16 Crossed Above 50 DMA Bullish 0.00%
Jan 16 MACD Bullish Centerline Cross Bullish 0.00%
Jan 16 Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
Jan 16 Pocket Pivot Bullish Swing Setup 0.00%
Jan 16 Wide Bands Range Expansion 0.00%
Jan 16 Up 3 Days in a Row Strength 0.00%
Jan 16 Upper Bollinger Band Touch Strength 0.00%
Jan 15 NR7 Range Contraction 9.09%
Jan 15 NR7-2 Range Contraction 9.09%
Jan 15 Wide Bands Range Expansion 9.09%

Older signals for CRIS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that has come back after surgery. The company also develops Erivedge, which is in phase II clinical trial for the treatment of operable nodular BCC; CUDC-427, a small molecule that has completed phase I clinical trial to promote cancer cell death in breast cancer and other solid tumors, and hematological cancers; and CUDC-907, a small molecule, which is in phase I clinical trial for the treatment of advanced lymphoma and multiple myeloma. In addition, it develops CUDC-101 that has completed phase I dose escalation clinical trial for the treatment of refractory solid tumors; and phase I expansion trial for the treatment of breast, gastric, head and neck, liver, or non-small cell lung cancers. Further, the company develops Debio 0932 that is in phase Ib expansion study for the treatment of solid tumors; and in a phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. It has collaborations with Genentech, Inc. for the development of Erivedge; and Debiopharm S.A. for the development and commercialization of Debio 0932. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Is CRIS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.2
52 Week Low 0.6
Average Volume 421,439
200-Day Moving Average 1.801
50-Day Moving Average 1.0392
20-Day Moving Average 0.8589
10-Day Moving Average 0.9587
Average True Range 0.1219
ADX 28.17
+DI 28.764
-DI 13.7725
Chandelier Exit (Long, 3 ATRs ) 0.8043
Chandelier Exit (Short, 3 ATRs ) 1.0257
Upper Bollinger Band 1.0956
Lower Bollinger Band 0.6222
Percent B (%b) 0.97
BandWidth 55.11701
MACD Line 0.0113
MACD Signal Line -0.0322
MACD Histogram 0.0435
Fundamentals Value
Market Cap 155.39 Million
Num Shares 144 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -2.16
Price-to-Sales 27.52
Price-to-Book 24.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.42
Resistance 3 (R3) 1.41 1.29 1.36
Resistance 2 (R2) 1.29 1.20 1.29 1.34
Resistance 1 (R1) 1.19 1.15 1.24 1.19 1.32
Pivot Point 1.07 1.07 1.09 1.07 1.07
Support 1 (S1) 0.96 0.98 1.01 0.97 0.84
Support 2 (S2) 0.84 0.93 0.84 0.82
Support 3 (S3) 0.74 0.84 0.80
Support 4 (S4) 0.74